Bovine Lactoferrin Induces Cell Death in Human Prostate Cancer Cells.
Vanessa P RochaSamir P C CamposCaroline A BarrosPablo TrindadeLeticia R Q SouzaTriciana G SilvaEtel Rodrigues Pereira GimbaAnderson Junger TeodoroRafael Braga GonçalvesPublished in: Oxidative medicine and cellular longevity (2022)
Bovine lactoferrin (bLf) is a multifunctional protein widely associated with anticancer activity. Prostate cancer is the second most frequent type of cancer worldwide. This study was aimed at evaluating the influence of bLf on cell viability, cell cycle progression, reactive oxygen species (ROS) production, and rate of apoptosis in the human prostate cancer cell line (DU-145). MTT assay and trypan blue exclusion were used to analyze cell viability. Morphological changes were analyzed through optical microscopy after 24 h and 48 h of bLf treatment. FITC-bLf internalization and cellular damage were observed within 24 h by confocal fluorescence microscopy. Cell cycle analyses were performed by flow cytometry and propidium iodide. For caspases 3/7 activation and reactive oxygen species production evaluation, cells were live-imaged using the high-throughput system Operetta. The cell viability assays demonstrated that bLf induces cell death and morphological changes after 24 h and 48 h of treatment compared to control on DU-145 cells. The bLf internalization was detected in DU-145 cells, G 1 -phase arrest of the cell cycle, caspase 3/7 activation, and increased oxidative stress on bLf-treated cells. Our data support that bLf has an important anticancer activity, thus offering new perspectives in preventing and treating prostate cancer.
Keyphrases
- cell cycle
- cell cycle arrest
- cell death
- induced apoptosis
- prostate cancer
- oxidative stress
- high throughput
- cell proliferation
- reactive oxygen species
- endoplasmic reticulum stress
- endothelial cells
- pi k akt
- radical prostatectomy
- signaling pathway
- high resolution
- dna damage
- flow cytometry
- squamous cell carcinoma
- drug delivery
- machine learning
- young adults
- ischemia reperfusion injury
- combination therapy
- cancer therapy
- diabetic rats
- heat shock protein
- newly diagnosed